Project Grant R01CA308127
Award Date 8/25/26
Completion Date 7/31/31
Dollars Obligated $389K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38103, USA
Similar Awards
- The National Cancer Institute awarded Emory University $602,847 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the N-glycan modification pathway as a therapeutic target for triple-negative breast cancer, particularly in BRCA1-deficient patients. The project examines the role of MAN1C1, a glycosyl hydrolase, in breast cancer progression, immune evasion, and therapeutic resistance. The research addresses a critical gap: approximately 50–70 percent of...
- The National Institutes of Health National Cancer Institute awarded Vanderbilt University Medical Center $695,884 on June 23, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate selective loss of HLA gene products in triple-negative breast cancer immunobiology. The research examines how tumor cells evade immune checkpoint inhibition through downregulation or deletion of MHC-I (major histocompatibility complex I) expression. Preliminary data from the recipient's...
- The National Cancer Institute awarded $668,878 to the University of Texas at Austin on April 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop novel antibody-drug conjugates targeting CD44 variant 9 for advanced and treatment-resistant breast cancer. The research addresses the clinical need for new therapeutic options for patients with triple-negative and heavily treated hormone receptor-positive metastatic breast cancer who have relapsed or progressed after current...
- The National Cancer Institute awarded $400,000 to Toomer Therapeutics, Inc. on September 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop small-molecule inhibitors of the E3 ubiquitin ligase ARIH1 as a targeted therapy for triple-negative breast cancer and other cancers. The project focuses on lead compound optimization, absorption-distribution-metabolism-excretion and pharmacokinetic studies to generate drug-like ARIH1 inhibitors, and preclinical efficacy studies of...
- The National Cancer Institute awarded The University of Kentucky Research Foundation $390,453 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate systemic crosstalk between tumor cells and neutrophils in triple-negative breast cancer. The project examines how triple-negative breast cancer tumors induce production of pro-tumor neutrophils and develops targeted strategies to selectively inhibit these subsets. The research focuses on tumor-derived granulocyte...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Methodist Hospital Research Institute a $403,485 Project Grant effective September 1, 2025, through August 31, 2027, under the Cancer Treatment Research program (CFDA 93.395). The research project focuses on the development of novel platinum-based polymers designed to induce robust reactive oxygen species (ROS) production with tumor-specific toxicity, specifically targeting triple negative breast cancer (TNBC). The...
- The National Cancer Institute awarded Vanderbilt University Medical Center $400,313 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to evaluate the AR antagonist darolutamide combined with standard-of-care therapy in triple-negative breast cancer patients, specifically those with the luminal androgen receptor subtype characterized by greater than 80 percent AR positivity by immunohistochemistry. The project addresses a significant clinical gap: the LAR subtype,...
- The National Cancer Institute awarded the University of Wisconsin–Madison $627,628 on July 20, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and test a novel anti-fibrotic peptide therapy for metastatic triple-negative breast cancer. The funded research develops PEG-FUD, a pegylated peptide that targets and inhibits fibronectin assembly in the tumor microenvironment. Excess fibronectin deposition in tumors limits chemotherapy penetration, excludes immune cell...
- The National Cancer Institute awarded the University of Kansas Medical Center Research Institute, Inc. $398,544 on April 8, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct pre-clinical evaluation of a highly selective SMARCA2 degrader in therapy-resistant triple-negative breast cancer. The research addresses mechanisms of resistance to neoadjuvant systemic therapy in triple-negative breast cancer patients with residual disease. The project leverages the recipient's...
- The National Cancer Institute awarded The University of Texas Health Science Center at San Antonio $609,846 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research targeting mucin-type O-glycosylation in EGFR mutant non-small cell lung cancer. The project runs through March 31, 2031, with place of performance in San Antonio, Texas. The work addresses treatment resistance in EGFR-mutant non-small cell lung cancer patients, who initially respond well to...